Efficacy and toxicity of compassionate ibrutinib use in relapsed/refractory chronic lymphocytic leukemia in Poland: analysis of the Polish Adult Leukemia Group (PALG)Elżbieta Iskierka‐Jazdzewska, Krzysztof Jamroziak, Jan Maciej Zaucha et al.|Leukemia & lymphoma/Leukemia and lymphoma|2017Cited by 39
Imatinib mesylate may induce long-term clinical response in FIP1L1-PDGFRα-negative hypereosinophilic syndromeGrzegorz Helbig, Sławomira Kyrcz‐Krzemień, Marek Hus et al.|Medical Oncology|2011Cited by 28